SCHEMBL20914272

SCHEMBL20914272

COc1cccc2oc(-c3c(C)[nH]c4c(-c5ccccc5)c(OCC(=O)O)nn4c3=O)nc12

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MEN1 O00255 1/20 0.37
▸ KMT2A Q03164 1/20 0.37
▸ F2RL3 Q96RI0 3/20 0.36
▸ CEPT1 Q9Y6K0 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ HSD17B10 Q99714 1/20 0.35
▸ TNKS O95271 1/20 0.35
▸ TNKS2 Q9H2K2 1/20 0.35
▸ PARP2 Q9UGN5 1/20 0.35
▸ MAT2A P31153 2/20 0.34
▸ POLB P06746 1/20 0.34
▸ SMN1; SMN2 Q16637 1/20 0.34
▸ TOP2A P11388 1/20 0.34
▸ MPO P05164 1/20 0.34
▸ PTGIR P43119 1/20 0.33
▸ PTGDR Q13258 1/20 0.33
▸ DHODH Q02127 1/20 0.33
▸ DCTPP1 Q9H773 1/20 0.33
▸ EDNRB P24530 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20914415 0.90 TNKS (0.39) MEN1KMT2AF2RL3HSD17B10TNKS
SCHEMBL20913920 0.89 TNKS (0.35) F2RL3CEPT1TNKSTNKS2PARP2
SCHEMBL20914255 0.86 TNKS (0.37) MEN1KMT2AF2RL3CEPT1TNKS
SCHEMBL20931219 0.85 TNKS (0.40) MEN1KMT2AF2RL3HSD17B10TNKS
SCHEMBL20837248 0.85 TNKS (0.37) MEN1KMT2AF2RL3CEPT1USP2
SCHEMBL20914061 0.84 CEPT1 (0.37) MEN1KMT2AF2RL3CEPT1MAT2A
SCHEMBL20914016 0.84 TNKS (0.39) MEN1KMT2AF2RL3HSD17B10TNKS
SCHEMBL20914083 0.83 TNKS (0.38) MEN1KMT2AF2RL3HSD17B10TNKS
SCHEMBL20914077 0.82 TNKS (0.37) MEN1KMT2AF2RL3TSHRHSD17B10
SCHEMBL20914212 0.82 TNKS (0.37) MEN1KMT2AF2RL3HSD17B10TNKS

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof ADURO BIOTECH INC. (US) 2020-08-11 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF CHINOOK THERAPEUTICS, INC. 2019-04-25 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10738056-B2 Pyrazolopyrimidinone compounds and uses thereof NLRP3, NLRP1, P2RX7 MEN1 2785/4885KMT2A 3490/4885F2RL3 1469/4885
US-20190119285-A1 PYRAZOLOPYRIMIDINONE COMPOUNDS AND USES THEREOF NLRP3, NLRP1, P2RX7 MEN1 2785/4885KMT2A 3490/4885F2RL3 1469/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback